Product Press Release
HERCULES, CA – January 25, 2017 – Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global provider of life science research and clinical diagnostic products, today announced the launch of Amplichek STI quality control, the third in a series of molecular infectious disease quality controls that the company has introduced for the molecular testing market.
Amplichek STI is a multi-analyte quality control product that monitors the performance of
in vitro laboratory nucleic acid testing procedures for the detection of Sexually Transmitted Infections including Chlamydia trachomatis (CT), Neisseria gonorrhoeae (NG or GC), and high risk strains of human papillomavirus (HPV). Amplichek STI is the only available IVD product that includes CT, NG/GC, and HPV and is designed to monitor analytical processes that include nucleic acid extraction and amplification in one control.
Molecular diagnostics is one of the fastest growing markets for in vitro diagnostics (IVD), with nucleic acid testing for Sexually Transmitted Infections (STI) expected to reach over $1.3B by 2020, according to a 2015 report by research firm MarketsandMarkets.
Learn more about Amplichek STI by visiting www.qcnet.com/molecular
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) develops, manufactures, and markets a broad range of innovative products and solutions for the life science research and clinical diagnostic markets. The company is renowned for its commitment to quality and customer service among university and research institutions, hospitals, public health and commercial laboratories, as well as the biotechnology, pharmaceutical, and food safety industries. Founded in 1952, Bio-Rad is based in Hercules, California, and serves more than 100,000 research and healthcare industry customers through its global network of operations.
The company employs more than 8,000 people worldwide and had revenues exceeding $2 billion in 2015. For more information, please visit www.bio rad.com.
Bio-Rad Forward-Looking Statements
This release may be deemed to contain certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements we make regarding plans to introduce products to the molecular diagnostics testing market and our development and launch of new products. Forward-looking statements generally can be identified by the use of forward-looking terminology such as “plan”, “believe,” “expect,” “anticipate,” “may,” “will,” “intend,” “estimate,” “continue,” or similar expressions or the negative of those terms or expressions, although not all forward-looking statements contain these words. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. These risks and uncertainties include our ability to develop and market new or improved products, our ability to compete effectively, international legal and regulatory risks, and product quality and liability issues. For further information regarding our risks and uncertainties, please refer to the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operation” in Bio-Rad’s public reports filed with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and our Quarterly Report on Form 10-Q. Bio-Rad cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. We disclaim any obligation to update these forward-looking statements.
Bio-Rad Laboratories, Inc.
Tina Cuccia, Corporate Communications